JC17 Rec'd PCT/PTO 3 0 MAR 2005

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Original) Hollow nanoparticles that comprise particle-forming first proteins, containing a bio-recognizing molecule for recognizing a specific cell, wherein at least one of the first proteins interacts with a second protein forming a capsid structure.

Claim 2. (Original) The hollow nanoparticles as set forth in claim 1, wherein the first protein comprises a hepatitis B virus surface-antigen protein.

Claim 3. (Original) The hollow nanoparticles as set forth in claim 2, wherein the first protein comprises a hepatitis B virus surface-antigen protein whose hepatocyte recognition site is modified to another bio-recognizing molecule.

Claim 4. (Original) The hollow nanoparticles as set forth in claim 3, wherein the first protein comprises a hepatitis B virus surface-antigen protein whose hepatocyte recognition site is modified to a beta-cellulin or a basic fibroblast growth factor.

Claim 5. (Currently Amended) The hollow nanoparticles as set forth in claims1-through 4, wherein the second protein comprises a hepatitis B virus core-antigen protein.

Claim 6. (Currently Amended) The hollow nanoparticles as set forth in claims-1-through 5, wherein the hollow nanoparticles are formed by transferring a gene encoding the first protein and a gene encoding the second protein to a single eukaryotic cell by separate vectors, so that the respective genes are coexpressed in the eukaryotic cell.

Kuroda et al. Appl. No. To be assigned March 30, 2005

Claim 7. (Original) The hollow nanoparticles as set forth in claim 6, wherein the eukaryotic cell is a yeast cell.

Claim 8. (Currently Amended) The hollow nanoparticles as set forth in claims 6 or 7, wherein the gene encoding the second protein is transferred by a vector having an Aureobasidin A-sensitive gene.

Claim 9. (Currently Amended) A drug that is made of the hollow nanoparticles as set form in any one of claims 1through 8, wherein a target cell substance is encapsulated in the hollow nanoparticles.

Claim 10. (Original) A disease treating method using the drug as set forth in claim 8.